Dr Andrei V Gudkov (University of Illinois) started the symposium talking about`New cellular factors modulating the tumor suppressor function of p53'. He began his talk by pointing out that the function of p53 is mediated by numerous cellular factors acting up-, downstream or in cooperation with this tumor suppressor, many of which remain unknown. He continued by describing two genetic approaches which have been applied in his laboratory to identify these factors, including the genetic suppressor element (GSE) methodology and microarray cDNA expression profiling. The GSE approach involves selection of biologically active elements from retroviral libraries of randomly fragmented cDNAs, GSEs, fragments of cDNAs acting as dominant negative mutants or antisense RNA, suppress the function of their parental genes and can be used for characterization of known and identi®cation of new genes. Genetic elements with anti-p53 activity were isolated from GSE libraries of subtracted and normalized cDNA libraries. One of the GSE-corresponding genes was found to encode a novel growth inhibitory, nuclear protein, termed p33ING1, that is a component of the p53 signaling pathway which cooperates with p53 in negative regulation of cell proliferation by modulating p53-dependent transcriptional activation. Characterization of other putative members of the p53 pathway isolated through the GSE approach is underway. On the other hand, human and mouse cDNA expression arrays were used for the detection of unknown p53-responsive genes in human ®broblasts and in the organs of mice. More than 50 new p53 responders were found. The majority of the identi®ed genes were observed to be tissue speci®c and to encode dierent classes of proteins indicating new mechanisms of p53-dependent growth regulation.
Dr Yuri Lazebnik (Cold Spring Harbor Laboratories) spoke about`Caspases which are considered as Enemies Within'. He pointed out that two main problems of chemotherapy are toxicity to normal cells and failure to eciently kill cancer cells. Both problems stem from the indirect mechanism by which both chemotherapeutic drugs and irradiation kill. They damage cells, both normal and cancerous, and this damage is then translated through multiple steps into cell death that appears to be mediated by caspases, a family of proteases that are the core of the apoptotic machinery. When any of the steps required to induce death is compromised, as often happens during carcinogenesis or treatment, the therapy fails. A possible solution for this problem is to design a treatment that will activate capases directly. However, how this can be done selectively in cancer cells is not clear. One approach may come from the observation that oncoproteins that deregulate cell cycle, activate caspases and induce apoptosis. An implication of this observation is that oncogene expression generates a pro-apoptotic signal that is present in transformed but absent in normal cells. When this signal is uncoupled from the apoptotic machinery transformed cells can survive and become resistant to chemotherapeutic drugs. In principle, restoring the link between the signal and the apoptotic machinery should selectively kill transformed cells because although untransformed cells have the machinery they lack the signal. To investigate how the apoptotic machinery is linked to oncogene expression. Dr Lazebnik and colleagues have developed a cell-free system that mimics oncogenedependent apoptosis. Using this system, recent ®ndings regarding the dissection of the biochemical mechanisms of oncogene-dependent apoptosis were described.
Dr E Premkumar Reddy (Fels Institute, Temple University) talked about recent exciting ®ndings in his laboratory regarding`JAK-STATs dedicated signaling pathways'. Interaction of IL-3 with its receptor is known to activate STAT-3 via phosphorylation of Tyrosine 701, which facilitates its dimerization and translocation to the nucleus, leading to the transcription of its target genes. In this context, the work conducted in Dr Reddy's laboratory, has been aimed at investigating the nature of tyrosine kinases that mediate STAT-3 phosphorylation during IL-3-mediated activation of myeloid cell proliferation. It was observed that interaction of IL-3 with its receptor leads to the activation of c-Src kinase activity, which in turn facilitated the binding of c-Src to STAT-3. This association was observed to lead to the phosphorylation of STAT-3, thereby allowing this transcription factor to translocate to the nucleus. Expression of a dominant negative mutant of src (AMSrc) in these cells resulted in a block to IL-3 mediated phophorylation of STAT-3, and its ability to bind to DNA. On the other hand, expression of a dominant negative mutant of JAK2 (JAK2KE) was found to have no eect on IL-3-mediated activation of STAT-3. Also, it was observed that AMSrc does not aect the phosphorylation of JAK2, suggesting that JAK and STAT phosphorylation events are mediated by two independent pathways. Inhibition of c-Src activation by AMSRc, which leads to a block to STAT-3 activation, resulted in a dramatic inhibition of cell proliferation mediated by IL-3. However, expression of AMSrc did not activate apoptotic pathways. In contrast, expression of JAK2KE resulted in accelerated apoptosis of 32Dc13 cells grown in the absence of IL-3 with concomitant downregulation of Erk-2 kinase activity. These results suggest that the Src family of kinases mediate the phosphorylation of STATs and play a critical role in signal transduction pathways associated with myeloid cell proliferation, while JAK kinases mediate the activation of the Erk-2 pathway which appears to provide anti-apoptotic signals. Thus, the activation of JAKs and STATs appear to be two independent but related events, which dictate two separate biological outcomes, the combination of which results in proliferation and survival of myeloid precursor cells.
Dr Michael Greenberg (Harvard University) spoke about`Signal transduction pathways that regulates dierentiation and survival in the developing nervous system'. He started by emphasizing the role of extracellular stimuli in eliciting a variety of cellular responses that are critical for cell proliferation, dierentiation, and survival during the development of the nervous system. Switching to his own research he pointed out that work in his laboratory is aimed at identifying the signal transduction pathways that mediate the responses of cells in the developing nervous system to neurotrophic factors and neurotransmitters. In particular the mechanisms by which neurotrophic factors promote neuronal survival and suppress apoptosis, are being investigated. Neurotrophic factors can promote cell survival by activating the phosphatidylinositide-3'-OH kinase and its downstream target, the serine-threonine kinase Akt. However, the mechanism by which Akt functions to promote survival has not been well understood. Research conducted in Dr Greenberg's laboratory has found that growth factor activation of the PI3'K/Akt pathway culminates in the phosphorylation of the BCL-2 family member BAD, thereby suppressing apoptosis and promoting cell survival. Akt phosphorylates BAD in vitro and in vivo, and blocks the BADinduced death of primary neurons in a site-speci®c manner. These ®ndings de®ne a mechanism by which growth factors directly inactivate a critical component of the cell-intrinsic death machinery. In an eort to relate these studies to neurological diseases that result in neuronal cell death, he concluded his seminar describing recent work aimed at developing cellular models that recapitulate in cultured neurons the neuronal cell death that is seen in patients with Huntington's Disease (HD).
Dr Richard Kolesnick's (Memorial Sloan-Kettering Cancer Center) talk has been focused at`Stress signals for apoptosis, including ceramide and c-Jun kinase/ stress-activated protein kinase'. Dr Kolesnick started his talk pointing out that mammalian systems respond to environmental stress by either adapting or undergoing programmed cell death. While there is general agreement that the caspase family of proteases serve as the eectors of the apoptotic death response, the signaling apparatus involved in the decision to activate the caspase system is less clear. In the past few years, the sphingomyelin and c-Jun kinase (JNK)/stressactivated protein kinase (SAPK) pathways, have been linked to the death response in many cellular systems. These signaling sysems are found throughout the animal kingdom, and for ceramide signaling conserved through yeast. Since yeast does not undergo apoptosis, the sphingomyelin pathway appears evolutionarily older than the caspase-mediated death programs. He continued his lecture reviewing the role of these systems in induction of apoptosis.
Starting with ceramide, he pointed out that the sphingomyelin pathway is initiated by hydrolysis of the phospholipid sphingomyelin (N-acylsphingosin-1-phosphocholine) which is preferentially concentrated in the plasma membrane of mammalian cells. Sphingomyelin hydrolysis occurs via the action of sphingomyelin speci®c forms of phospholipase C, termed sphingomyelinases (SMases). Ceramide, generated by this reaction, acts as a second messenger and initiates cell type speci®c signaling. Apoptosis is only one of many reported eects in response to ceramide generation. However, it is a commonly reported event.
Cellular SMases are de®ned by their pH optima as either neutral or acid. Neutral sphingomyelinase (NSMase) is found in many, if not all, tissues. NSMases display a pH optimum of 7.4, and are either membrane-bound and Mg 2+ -dependent, or cytosolic and cation-independent. The gene or genes encoding the mammalian NSMase require identification. Acid sphingomyelinases (ASMases), possessing optimum-pH between 4.5 ± 5.5, are found in all mammalian cells as low molecular weight intracellular or high molecular weight secreted forms. This appears to re¯ect post-translational processing of the primary gene product. The secreted form of ASMase is Zn 2+ -stimulable and, in some conditions, can function at neutral pH. In contrast, the lysosomal form is not Zn 2+ stimulable. Tabas and co-workers found that macrophages, ®broblasts, and endothelial cells secrete substantial amounts of the high molecular weight form of ASMase. Secretion of this form is increased by cytokine stimulation, perhaps by increasing the¯ux of the ASMase precursor through the Golgi-secretory pathway. There is emerging evidence suggesting that caveolae, putative plasma membrane microdomains, may be important sites for ligand-induced sphingomyelin hydrolysis via ASMase. Both NSMase and ASMase have been implicated in stress-induced apoptosis.
Diverse stresses (oxidative, UV, ionizing radiation, heat,¯ow, cytokines, chemotherapeutic agents) activate the sphingomyelin pathway during signaling of the death response. In most instances, analogs of ceramide but not other lipid second messengers mimic the induction of the death response, providing evidence that ceramide generation plays a direct role in the apoptotic response. This eect is stereospeci®c as analogs of the natural precursor for ceramide, dihydroceramide, fail to induce apoptosis. Further, genetic models of SMase de®ciency which lack ceramide generation do not undergo apoptosis upon exposure to stress. B cells from patients with Niemann ± Pick disease (NPD) fail to respond to ionizing radiation with ceramide generation or apoptosis, and retroviral transfer of the ASMase gene restores both events. Similarly, ASMase knockout mice present a de®cit in radiation-and endotoxin/TNF-induced ceramide generation and apoptosis in endothelium, but no defect in p53-mediated death of thymocytes.
Ceramide may signal the death response by two independent, but perhaps coordinate mechanisms. Evidence suggests that ceramide may signal transcriptionally dependent apoptosis, perhaps via the JNK/ SAPK system, or transcriptionally independent apoptosis via a pathway involving mitochondrial dysfunction. Transcriptionally dependent apoptosis may involve either the up-regulation of pro-apoptotic proteins (Fas ligand, TNFoc, TRAIL etc) or downregulation of anti-apoptotic proteins (Bcl-2). In this regard, Debatin and coworkers recently found that NPD ®broblasts were de®cient in UV-and anthracycline-induced ceramide generation and apoptosis, which involved transcriptional upregulation of CD95 ligand, and that ceramide analogs restored the death response. Ceramide also signals apoptosis by aecting mitochondrial function. Numerous reports document a form of ceramide-induced apoptosis that is inhibited by Bcl-2, whereas Bcl-2 usually fails to inhibit apoptosis initiated by overexpression of caspases. Kroemer and colleagues have shown that ceramide signals mitochondrial permeability transition, reactive oxygen species generation and release of apoptosis initiating factor in cytoplasts from muring 2B4.11 T cells. This eect was indirect and required unknown cytosolic signaling molecules.
In summary, the sphingomyelin pathway is a generic evolutionarily conserved stress response system that links downstream to caspase-mediated death by both transcriptionally-dependent and independent pathways.
Switching to JNK/SAPK, Dr Kolesnick stressed that like the sphingomyelin pathway, the JNK/SAPK pathway is evolutionarily conserved and represents one of three MAPK cascades. In contrast to the extracellular response kinase (ERK) pathway which transmits primarily mitogenic/dierentiated signals, the JNK cascade is a stress response system activated by stresses similar to those signaling ceramide generation. The JNK/SAPK family is comprised of three separate genes which can be alternatively spliced to as many as 10 isoforms. Stresses stimulate an ever enlarging set of upstream kinases that transmit signals through a smaller group of MAP kinase kinases to activate the JNK family members. As observed with ceramide signaling, the outcome of JNK signaling is cell-and context-dependent, with growth, dierentiation or apoptosis as potential outcomes.
About 175 papers address the role of JNK/SAPK in induction of the apoptotic response. About 2/3 of these ®nd a role for JNK/SAPK in this process. The other 1/ 3 of the reports provide evidence that JNK/SAPK is anti-apoptotic. The evidence that JNK/SAPK is proapoptotic derives from studies that show that these kinases are turned on rapidly in cells destined to undergo an apoptotic response, that anti-sense inhibition or the use of dominant negative constructs attenuates the apoptotic response, and in a recent publication by the use of a knock-out mouse. In the latter studies, in mice de®cient in JNK3, which is restricted to the brain, there was a reduction in seizure activity and hippocampal apoptosis in response to the excitotoxic glutamate-receptor agonist kainic acid. In many instances, the ERK cascade appears to attenuate JNK/SAPK mediated apoptosis.
The diering results obtained in dierent studies on the role of JNK/SAPK family members is undoubtedly contributed to by the quality of the available reagents. None of the antibodies generated so far distinguish adequately between the JNK/SAPK family members, making it nearly impossible to assign pro-or antiapoptotic functions in any particular cell or in response to any particular stress. This similarly impinges on our ability to de®ne subcellular localization or speci®c isoforms during induction of apoptosis. Furthermore, the upstream kinases that regulate JNK/ SAPK isoforms during speci®c signaling events are for the most part unknown. Nevertheless, some themes have emerged over the last year. It appears that TRAF2 signaling of JNK/SAPK activation is antiapoptotic, whereas ceramide signaling is pro-apoptotic. With respect to this latter event cereamide appears capable of signaling JNK/SAPK activation either through a pathway activated by the small G-protein rac1 or through TAK1. In this regard, Dong and coworkers found that ASMase activity is essential for UV-induced JNK activation as NPD cells were defective in this response and ceramide analogs bypassed the blockade (16). Clearly, better reagents are necessary to delineate the mechanism of JNK/SAPKmediated apoptosis.
Dr Barbara Homan's (Fels Institute, Temple University) talk was aimed at discussing the`Roles of myc, myb and E2F as negative regulators of terminal dierentiation', using hematopoietic cells as model system. Dr Barbara Homan started her talk pointing out that candidate genes for negative regulators of dierentiation are genes which promote proliferation and cease to be expressed following induction of dierentiation. Three genes found to be negative regulators of terminal myeloid dierentiation are cmyc, c-myb and E2F-1. Using the myeloid leukemic M1 cell line, which undergoes terminal dierentiation in response to interleukin-6 (IL-6), and corroborating the ®ndings with normal myeloid cells from bone marrow, the role of c-myc, c-myb and E2F-1 were studied, in her laboratory, in collaboration with Dr Dan Liebermann. Deregulated expression of the protooncogene c-myc was found to block dierentiation at an intermediate stage. In contrast to cells in which cmyc is downregulated, these cells continued to proliferate, but with an increased doubling time relative to cells not induced to undergo differentiation. It was observed that this population of cells had reduced viability, with a subpopulation of the cells undergoing apoptosis which is p53 independent. Deregulated expression of c-myb also blocked myeloid dierentiation but at an earlier stage and did not promote cell death. In order to characterize the molecular machinery underlying the c-myc-mediated apoptotic response, a comparison of the dierential expression patterns of key gene products in M1myc and M1myb cells following treatment with IL-6 was carried out. These studies revealed that bcl-2 was downregulated, p15 was induced and Rb was hypophosphorylated in M1myc cells but not M1myb cells. Further analysis demonstrated that neither downregulation of Bcl-2, nor induction of p15 and the hypophosphorylated state of Rb accounted for the myc-mediated apoptotic response. Deregulated expression of E2F-1 also blocked dierentiation, but at the immature blast stage, and the cells proliferated normally, not undergoing apoptosis following treatment with IL-6. In response to IL-6, p15, p16 and Rb hypophosphorylation were induced. These data demonstrated uncoupling of p15, p16 and Rb hypophosphorylation from dierentiation-associated growth arrest. Finally, it has been demonstrated that deregulated expression of E2F prevented the loss of leukemogenicity of M1 cells normally induced by IL-6. Dr Daniel G Tenen (Harvard Medical School), described studies, conducted in his laboratory in collaborations with investigators at the Baylor College of Medicine and at the Washington University Medical School, that were aimed at understanding thè Regulation of hematopoietic cell development by lineage speci®c transcription regulators'. He started his talk pointing out that the work performed in his laboratory is primarily interested in isolating and characterizing factors which play a role in the dierentiation of hematopoietic stem cells into dierent speci®c lineages, with particular focus on myeloid (granulocyte and monocyte) dierentiation in normal and leukemic cells. His recent studies have focused on investigating the expression and function of two master transcription factors which are regulators of myeloid development: the Ets factor PU.1 and CCAAT/enhancer binding protein alpha (C/EBP alpha). His studies have demonstrated a role for PU.1 and C/EBP alpha in the myeloid speci®c expression of a number of important myeloid genes, including the three myeloid CSF (GM, M, and G) receptors, and expression and knockout studies of PU.1 and C/EBP alpha show they play a major role in development of speci®c myeloid lineages.
C/EBP alpha is a basic leucine zipper transcription factor which has been shown to serve as a master regulatory switch in several dierentiation systems, including adipocyte and liver development, and also as a tumor suppressor gene which can inhibit cell proliferation by activating p21. C/EBP alpha regulates a number of myeloid-speci®c genes, and analysis of C/ EBP alpha knockout mice provided evidence for a necessary and speci®c role of this factor during hematopoiesis in vivo: the animals were absolutely de®cient in granulocytes, whose dierentiation was blocked at an early stage, while the development of other hematopoietic lineages remained undisturbed.
Previously, Dr Tenen's group has demonstrated that granulocyte colony-stimulating factor receptor (G-CSFR) mRNA was downregulated and granulocyte maturation blocked in C/EBP alpha ±/± mice (Zhang et al., PNAS, 94: 569, 1997 ). This phenotype is distinct from that of G-CSFR ±/±mice, which have a quantitative defect in granulopoiesis, but mature granulocytes are detected at a reduced level (12% of wild type) in the peripheral blood (Liu et al., Immunity, 5: 491, 1996) . These results suggest that other C/EBP alpha regulated cytokine receptors in addition to the G-CSFR regulate granulocyte development. We now demonstrate loss of expression of interleukin-6 receptor (IL-6R), but not the IL-6 transducer (gp130), by Northern blot analysis. Quantitative RT ± PCR demonstrated that IL-6R mRNA in C/EBP alpha ±/± fetal liver is 170-fold less than that observed in wild type, and that G-CSFR mRNA is decreased 17-fold. FACS analysis using biotinylated G-CSF and IL-6 revealed no detectable G-CSF or IL-6 receptor protein on the surface of C/EBP alpha ±/± spleen or fetal liver hematopoietic cells. Concordant with the drastically reduced receptor levels, no colonies were obtained in methylcellulose CFU assays in response to IL-6 and G-CSF stimulation of hematopoietic precursors from C/ EBP alpha ±/± fetal liver. Finally, we demonstrated that the block in granulopoiesis in the C/EBP alpha ±/± fetal liver hematopoietic cells can be rescued in vitro by adding soluble IL-6R and IL-6 into the CFU assay, or alternatively by retroviral transduction of the G-CSF receptor and subsequent G-CSF administration. These studies suggest that in addition to G-CSF receptor, C/ EBP alpha directly or indirectly regulates the expression of the IL-6 receptor. Furthermore, the failure of granulopoiesis in vitro observed with C/EBP alpha ±/± fetal liver hematopoietic cells in response to IL-6 and G-CSF can be compensated by restoration of IL-6 or G-CSF receptor expression, suggesting that loss of these two receptors alone plays a signi®cant role in the absolute block in granulocyte maturation observed in vivo.
In order to further delineate the role of C/EBP alpha in human granulopoiesis, we studied its expression and function in human myeloid cell lines and primary hematopoietic cells. Using puri®ed populations of human bone marrow cells, he shows that the expression of C/EBP alpha during hematopoietic development is initiated with the commitment of mutlipotential precursor cells to the myeloid lineage. It is also speci®cally upregulated during granulocytic dierentiation of normal human CD34 + cells and myeloid cell lines. Conversely, dierentiation along the monocytic pathway results in rapid downregulation of C/EBP alpha gene expression. Conditional expression of C/EBP alpha from a zinc-inducible metallothionein promoter in stably transfected U937 results in granulocytic maturation over a period of 2 weeks, as determined by cell morphology, NBT assay and upregulation of mRNA for the myeloid maturation marker CD18 and the granulocyte-speci®c G-CSF receptor. Strikingly, induced C/EBP alpha was also capable of activating neutrophil-speci®c genes encoding the secondary granule proteins lactoferrin and human neutrophil collagenase, which cannot otherwise be induced in these cell lines, even after chemical stimulation of granulocytic dierentiation. Granulocytic dierentiation was also observed in stable lines treated with zinc for only 2 days. Conditional expression of C/EBP alpha does not prevent monocytic dierentiation by TPA if cells express C/EBP alpha for less than 7 days. However, the cells expressing C/EBP alpha for over 7 days enter an irreversible stage of neutrophilic dierentiation resistant to monocytic induction. In summary, upon upregulation of C/EBP alpha, U937 cells progress into stages of dierentiation which are more mature than those invoked by known chemical inducers, such as retinoic acid. These results indicate that C/EBP alpha can serve as a myeloid dierentiation switch acting on bipotential myeloid precursors and directing them to mature to granulocytes.
Current eorts in the laboratory focus on understanding regulation, signal transduction pathways, and interacting partners of PU.1 and C/EBP alpha. The research is in the process of screening myeloid leukemias for abnormalities in structure and expression of these two genes, as well as mutations. Other projects directed at leukemogenic mechanisms include analysis of the eects of translocations found in AML on C/EBP alpha function, and models of murine leukemia using inducible expression of translocation fusion proteins, such as the Bcr-Abl protein. The long term goals of Dr Tenen's studies are to understand the abnormalities seen in acute myelogenous leukemia (AML), in which dierentiation of myeloid blasts is blocked, and to use these myeloid promoters as tools to drive lineage and stage speci®c expression of heterologous genes in recipient ES cells and transgenic mice, as a step toward gene therapy applications.
Dr George C Prendergast (The Wistar Institute) talked about the`Myc-Bin1 signaling pathway in cell death and dierentiation'. Starting his talk, he pointed out that myc is a key regulator of cell proliferation that when inappropriately regulated can drive apoptosis.
The regulatory mechanism(s) underlying this feature are of interest for their potential utility in the many cancer cells where Myc is deregulated. To gain insight into the mechanism, Dr Prendergast's group previously identi®ed Bin1 as a novel protein that interacts with the crucial N-terminal`Myc box', regions that are hotspots for mutation in cancer cells. Bin1 is a shortlived nuclear phosphoprotein with features of a tumor suppressor that is ubiquitously expressed normally but missing or altered in the majority of tumor cells examined to date. Bin1 associates with Myc in vitro and in vivo and selectively inhibits its ability to transactivate minimal promoters and the Myc target genes ODC and prothymosin.
Using genetic methods, Dr Prendergast's group has examined the function of Bin1 in model systems for cell dierentiation and Myc-mediated apoptosis. In C2C12 myoblasts, inhibition of Bin1 was observed to prevent the ability of cells to exit the cell cycle and dierentiate. Conversely, ectopic Bin1 slowed cell growth and promoted more vigorous dierentiation after it was induced. In ®broblasts containing deregulated Myc, inhibition of Bin1 suppressed the ability of Myc to drive apoptosis. Thus, Bin1 may function normally in controlling cell cycle exit and dierentiation. However, if Myc is deregulated and cells cannot exit the cycle and dierentiate fully, Bin1 may generate an abortive apoptosis signal.
Pro-apoptotic and pro-dierentiation functions for Bin1 support the hypothesis that it is a tumor suppressor. Also, frequent loss of function and alterations in Bin1 (through both genetic and epigenetic mechanists) have been observed in a variety of cancers including breast and prostate cancer. Bin1 maps to a rnid-2q hotspot for chromosomal deletions in prostate cancer, and LOH occurs at the Bin1 locus in that cancer. Evidence that aberrant splicing may be the mechanism by which loss of function occurs in prostate cancer has been obtained. Presumptive aberrant forms of Bin1 that accumulated speci®cally in the malignant cells in sections of 29/30 cases of prostate cancer may oer diagnostic and/or prognostic utility.
Dr Ruth J Muschel (University of Pennsylvania) spoke about work, conducted in collaboration with Dr WG McKenna, aimed at gaining a better understanding of radioresistance and the cell cycle. Work conducted in her laboratory has shown that introduction of the ras oncogene into rat embryo ®broblasts results in the acquisition of increased resistance to radiation. Subsequent studies have been focused at studying why these cells have increased resistance and whether that resistance can be blocked. Cells undergo a delay in G2 after DNA damage induced by radiation and this delay is markedly prolonged in the radioresistant cells bearing the ras oncogene. The delay is also accompanied by depression in the levels of cyclin B1, a protein required for the G2 to M transition. To demonstrate the importance of decreased levels of cyclin B1 in the radiation response, her group has developed a cell line with an inducible vector for cyclin B1 and was able to show that restoration of cyclin B1 after radiation greatly shortened the G2 delay con®rming the importance of cyclin B1 in the G2 delay. However, the delay was not eliminated indicating that other mechanisms must also play a role. Preliminary experiments suggest that blockade of the cytoplasmic to nuclear transport of cdc2 may also occur after radiation. Since many human tumors bear mutations in the ras oncogene, the development of strategies that could block the ras mediated protection against radiation might be used to sensitize tumor cells without altering the response of the adjacent host cells. Since ras must be farnesylated in order to be active, they have used inhibitors to farnesyl transferase to determine whether ras-bearing cells could be sensitized to ionizing radiation. In fact cells bearing H-ras mutations were readily sensitized while cells without ras mutations were not aected. Although the blockade of farnesylation proved to be more dicult for K-ras than H-ras, it was also possible to block K-ras farnesylation, and in the cells bearing the K-ras oncogene, but not other cells this blockade resulted in radiosensitization. Thus, the inhibition of ras action might prove to be a feasible method to radiosensitize human tumor cells while leaving the host cells unaected.
Finally, Dr Donald Kufe (Dana Farber Cancer Institute, Harvard Medical School) described studies that were performed in his laboratory addressing thè Role for the c-Abl tyrosine kinase in genetic recombination'. The c-Abl nonreceptor tyrosine kinase is activated in cells exposing to ionizing g-radiation (IR) and certain other DNA-damaging agents. IR induces DNA double-strand breaks (DSBs) and thereby activates the DNA dependent protein kinase (DNA-PK), a complex of DNA-PKcs and Ku, that is essential for DNA repair and recombination. DNA-PK phosphorylates and activates c-Abl. In a potential feedback mechanism, c-Abl-mediated phosphorylation of DNA-PK inhibits DNA-PK activity. Other ®ndings indicate that c-Abl interacts with the ataxia telangictasia mutated (ATM) gene product which also functions in the response to DNA lesions. Whereas DNA DSBs accumulate during DNA synthesis, recontamination and mitosis, the functional role of c-Abl-DNA-PK and c-Abl-ATM interactions presumably resides in the regulation of genomic stability. This hypothesis is supported by recent studies demonstrating that c-Abl regulates the essential Rad51 protein, a homologue of bacterial RecA, which functions in DNA DSB repair and recombination. Phosphorylation of Rad51 by cAbl inhibits the binding of Rad51 to DNA and the function of Rad51 in ATP-dependent DNA strand exchange reactions. The ®ndings that c-Abl interacts with DNA-PK, ATM and Rad51 have supported a potential role in other cell processes, such as meiotic recombination, that are also associated with DNA strand interruptions. Indeed, c-Abl is expressed in testes and predominantly in pachytene spermatocytes of meiosis. The results show that c-Abl interacts directly with meiotic chromosomes. Moreover, in concert with a requirement for c-Abl at the pachytene stage, testes from c-abl±/± mice exhibit profound defects in spermatogenesis. Since crossing-over occurs at the pachytene stage, one could propose that c-Abl is involved in the regulation of meiotic recombination. Finally, it is intriguing that c-abl±/± mice die as neonates with defective lymphopoiesis, perhaps as a result of defective V(D)J recombination. Taken together, the available evidence support a role for cAbl in the regulation of genetic recombination. In this model, activation of c-Abl by IR-induced DSBs represents otherwise physiological response to DNA strand interruptions that occur as a consequence of normal cellular events.
